Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib

被引：1

作者：

Danese, Silvio ^{[1
,2
]}

Panes, Julian ^{[3
]}

Dubinsky, Marla ^{[4
]}

Guo, Xiang ^{[5
]}

Yndestad, Arne ^{[6
]}

Schreiber, Stefan ^{[7
]}

Chaparro, Maria ^{[8
]}

机构：

[1] IRCCS San Raffaele Hosp, Gastroenterol & Endoscopy, Milan, Italy

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] Hosp Clin Barcelona, Dept Gastroenterol, Inflammatory Bowel Dis Unit, IDIBAPS,CIBEREHD, Barcelona, Spain

[4] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein Inflammatory Bowel Dis C, New York, NY USA

[5] Pfizer Inc, Collegeville, PA 19426 USA

[6] Pfizer Inc, Oslo, Norway

[7] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Internal Med 1, Kiel, Germany

[8] Hosp Univ La Princesa, Univ Autonoma Madrid UAM, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Unit, Madrid, Spain

来源：

CROHNS & COLITIS 360 | 2024年 / 6卷 / 04期

关键词：

ulcerative colitis; tofacitinib; safety; INFLAMMATORY-BOWEL-DISEASE; RHEUMATOID-ARTHRITIS; CANCER;

D O I：

10.1093/crocol/otae049

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Higher age (65 years or over), long-term smoking, or a previous cardiovascular event (such as heart attack) should be considered safety risks when considering treatment with tofacitinib versus tumor necrosis factor inhibitors for people with ulcerative colitis.

引用

页数：7

共 26 条

[1] The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Alatab, Sudabeh
Sepanlou, Sadaf G.
Ikuta, Kevin
Vahedi, Homayoon
Bisignano, Catherine
Safiri, Saeid
Sadeghi, Anahita
Nixon, Molly R.
Abdoli, Amir
Abolhassani, Hassan
Alipour, Vahid
Almadi, Majid A. H.
Almasi-Hashiani, Amir
Anushiravani, Amir
Arabloo, Jalal
Atique, Suleman
Awasthi, Ashish
Badawi, Alaa
Baig, Atif A. A.
Bhala, Neeraj
Bijani, Ali
Biondi, Antonio
Borzi, Antonio M.
Burke, Kristin E.
Carvalho, Felix
Daryani, Ahmad
Dubey, Manisha
Eftekhari, Aziz
Fernandes, Eduarda
Fernandes, Joao C.
Fischer, Florian
Haj-Mirzaian, Arvin
Haj-Mirzaian, Arya
Hasanzadeh, Amir
Hashemian, Maryam
Hay, Simon, I
Hoang, Chi L.
Househ, Mowafa
Ilesanmi, Olayinka S.
Balalami, Nader Jafari
James, Spencer L.
Kengne, Andre P.
Malekzadeh, Masoud M.
Merat, Shahin
Meretoja, Tuomo J.
Mestrovic, Tomislav
Mirrakhimov, Erkin M.
Mirzaei, Hamed
Mohammad, Karzan A.
Mokdad, Ali H.
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (01): : 17 - 30
[2] Comorbidities in inflammatory bowel disease: a call for action
Argollo, Marjorie
Gilardi, Daniel
Peyrin-Biroulet, Carina
Chabot, Jean Francois
Peyrin-Biroulet, Laurent
Donese, Silvio
[J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08): : 643 - 654
[3] Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
Axelrad, Jordan E.
Lichtiger, Simon
Yajnik, Vijay
[J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (20) : 4794 - 4801
[4] Bollen L, 2016, EUR J GASTROEN HEPAT, V28, P1, DOI 10.1097/MEG.0000000000000495
[5] Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Charles-Schoeman, Christina
Buch, Maya H.
Dougados, Maxime
Bhatt, Deepak L.
Giles, Jon T.
Ytterberg, Steven R.
Koch, Gary G.
Vranic, Ivana
Wu, Joseph
Wang, Cunshan
Kwok, Kenneth
Menon, Sujatha
Rivas, Jose L.
Yndestad, Arne
Connell, Carol A.
Szekanecz, Zoltan
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01) : 119 - 129
[6] Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
Curtis, Jeffrey R.
Regueiro, Miguel
Yun, Huifeng
Su, Chinyu
DiBonaventura, Marco
Lawendy, Nervin
Nduaka, Chudy, I
Koram, Nana
Cappelleri, Joseph C.
Chan, Gary
Modesto, Irene
Lichtenstein, Gary R.
[J]. INFLAMMATORY BOWEL DISEASES, 2021, 27 (09) : 1394 - 1408
[7] Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Dougados, Maxime
Soubrier, Martin
Antunez, Anna
Balint, Peter
Balsa, Alejandro
Buch, Maya H.
Casado, Gustavo
Detert, Jacqueline
El-zorkany, Bassel
Emery, Paul
Hajjaj-Hassouni, Najia
Harigai, Masayoshi
Luo, Shue-Fen
Kurucz, Reka
Maciel, Gabriel
Martin Mola, Emilio
Montecucco, Carlo Maurizio
McInnes, Iain
Radner, Helga
Smolen, Josef S.
Song, Yeong-Wook
Vonkeman, Harald Erwin
Winthrop, Kevin
Kay, Jonathan
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 62 - 68
[8] Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study
Grainge, Matthew J.
West, Joe
Card, Timothy R.
[J]. LANCET, 2010, 375 (9715) : 657 - 663
[9] Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study
Kirchgesner, Julien
Beaugerie, Laurent
Carrat, Fabrice
Andersen, Nynne Nyboe
Jess, Tine
Schwarzinger, Michael
[J]. GUT, 2018, 67 (07) : 1261 - 1268
[10] Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Kristensen, Lars Erik
Danese, Silvio
Yndestad, Arne
Wang, Cunshan
Nagy, Edward
Modesto, Irene
Rivas, Jose
Benda, Birgitta
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (07) : 901 - 910

← 1 2 3 →